A 56-year-old man presents with severe pain, redness, and swelling of his right ring finger. The pain began abruptly two days ago and reached its maximum intensity within several hours. Even light contact with the finger is painful.
He denies trauma, fever, or chills. Over the previous year, he has noticed several firm, pale nodules around the affected joint. He recalls two previous episodes of sudden great-toe pain that resolved without medical assessment.
His medical history includes hypertension treated with hydrochlorothiazide 25 mg daily, hyperlipidemia, and stage 3b chronic kidney disease. His eGFR has remained between 40 and 45 mL/min/1.73 m² for the past year. He has never received urate-lowering therapy.
He works as a construction manager, drinks three to four beers over a typical weekend; sometimes during one evening; and stopped smoking ten years ago. His mother has type 2 diabetes. He underwent an appendectomy at age 30.
His temperature is 37.2°C, heart rate 85/min, respiratory rate 16/min, and blood pressure 140/88 mmHg.
See image below.
Representative photograph of the lesions involving the right ring finger distal interphalangeal joint, provided for illustration
Image: Tausche A-K, Wunderlich C, Aringer M. Tophaceous Gout and Renal Insufficiency: A New Solution for an Old Therapeutic Dilemma. Case Reports in Medicine. 2011;2011:397646. Figure 1(a). © 2011 Anne-Kathrin Tausche et al. Reused under the article’s Creative Commons Attribution license; panel (a) extracted from the original figure.
Laboratory findings
Test | Result |
|---|---|
Serum urate | 9.8 mg/dL (3.5-7.2 mg/dL) |
White blood cell count | 7,800/mm³ (4,000-11,000/mm³) |
C-reactive protein | 15 mg/L (<10mg/L) |
eGFR | 42 mL/min/1.73 m² |
Potassium | 4.3 mmol/L (3.5-5.0 mmol/L) |
You arrive at the conclusion that the clinical assessment supports an acute gout flare with tophaceous disease.
Question
Which treatment strategy most appropriately manages both the current flare and his underlying gout?
A. Give prednisone 30 mg daily for 5 days. Start allopurinol 300 mg daily with colchicine prophylaxis, because visible tophi warrant rapid urate reduction.
B. Give prednisone 30 mg daily for 5 days. Start allopurinol 50 mg daily and titrate to the serum urate target; omit ongoing flare prophylaxis because prednisone covers treatment initiation.
C. Give prednisone 30 mg daily for 5 days. Start allopurinol 50 mg daily with subsequent titration and low-dose colchicine prophylaxis, individualized to kidney function and interacting medications.
D. Give prednisone 30 mg daily for 5 days. Start probenecid rather than allopurinol, because stage 3b CKD makes a xanthine oxidase inhibitor unsuitable.
Choose your answer before reading on.
The correct answer: C
This patient needs treatment for two different problems: the inflammation causing today’s pain and the urate deposition responsible for his tophi.
A short course of oral prednisone is a reasonable treatment for the current flare when NSAIDs are unsuitable. Prednisone 30 mg daily for 5 days falls within the short-course glucocorticoid approach recommended by EULAR. Clinical response should determine whether reassessment or further treatment is needed.
Tophi establish an indication for urate-lowering therapy. Allopurinol remains a preferred first-line option in CKD. Starting at 50 mg daily is appropriate for this degree of renal impairment, followed by gradual adjustment rather than leaving him indefinitely on the starting dose.
Low-dose colchicine serves a different purpose here: preventing additional flares while urate-lowering treatment is introduced and adjusted. A reasonable initial prophylactic regimen is 0.6 mg once daily, provided renal dosing assessment and medication review support its use.
Why the other answers are incorrect
A. The starting allopurinol dose is too high
The error is beginning at 300 mg daily, particularly in someone with CKD. Tophi justify sustained urate lowering, but do not justify bypassing a low starting dose.
The distinction is between the starting dose and the eventual effective dose. Some patients with CKD will need substantially higher maintenance doses after careful titration.
B. Five days of prednisone does not provide adequate ongoing prophylaxis
Prednisone treats the present episode. The risk of further flares during urate lowering extends beyond that short course.
ACR recommends anti-inflammatory prophylaxis for at least 3–6 months, with reassessment and continuation when flares persist. Omitting prophylaxis simply because a brief steroid course was prescribed leaves this risk unaddressed.
D. CKD does not make allopurinol unsuitable
Renal impairment changes how allopurinol is started and monitored; it does not automatically rule it out.
For CKD stage 3 or worse, ACR recommends a xanthine oxidase inhibitor over probenecid. Choosing probenecid specifically because this patient has CKD reverses that recommendation.
Clinical pearl
Treating the flare relieves today’s symptoms. Sustained urate lowering treats the disease. Kidney impairment makes thoughtful prescribing more important …. it does not remove the need for either.
What the question left out?
1. Doesn’t allopurinol have to wait until the flare settles?
No. ACR conditionally supports starting during a treated flare when urate-lowering therapy is indicated. However, this is an option, not a requirement: NICE generally recommends starting 2–4 weeks after the flare settles, unless flares are frequent. A planned delayed start can also be appropriate; indefinite deferral is the problem.
2. Isn’t colchicine contraindicated in CKD?
Moderate renal impairment does not automatically require not using colchicine. A reduced colchicine dose can be used, but close monitoring is necessary. For CKD Stage 3 (eGFR 30–59 mL/min), give 0.6 mg once daily. Colchicine can become dangerous with certain interacting drugs: combining it with strong CYP3A4 or P-glycoprotein inhibitors in a patient with renal impairment is contraindicated. Patients like him can frequently be on a statin, so extreme caution will have to be observed.
3. What about an intra-articular glucocorticoid shot?
For an accessible single joint, an intra-articular glucocorticoid is another option after infection has been appropriately excluded. Injection into a small finger joint depends on access and operator expertise.
4. Always watch out for septic arthritis
If the examination or course raises concern for infection, arrange aspiration and appropriate microbiological testing. Finding urate crystals does not exclude coexisting septic arthritis.
5. Complete the allopurinol safety review before the first dose.
Check baseline blood count, liver and kidney function. Review interacting drugs, particularly azathioprine or mercaptopurine. Complete indicated HLA-B*58:01 testing before the first dose. Explain that a new rash requires stopping allopurinol and obtaining urgent medical advice.
6. What is the urate target level?
You are starting allopurinol 50 mg daily now alongside flare treatment. Check serum urate approximately monthly during titration. Aim below 6 mg/dL; a target below 5 mg/dL can be considered because he has tophi.
9. Address the contributors and arrange follow up
Review whether hydrochlorothiazide can be replaced; losartan is possibly a reasonable alternative but watch the kidney function and serum potassium level closely. Discuss alcohol intake and medication adherence. Consider rheumatology referral given his tophi and stage 3b CKD. Explain that urate-lowering treatment is usually long term, including after symptoms improve.
Patient details and clinical findings are simulated; the photograph is a representative image from a separate published source.
Selected References:
1. Richette P, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29-42. doi: 10.1136/annrheumdis-2016-209707. PMID: 27457514.
2. FitzGerald JD, et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care Res (Hoboken). 2020;72(6):744-760. doi: 10.1002/acr.24180. PMID: 32391934.
3. NICE. Gout: diagnosis and management. Guideline NG219. 2022.
4. Ravn C, et al. Guideline for management of septic arthritis in native joints (SANJO). J Bone Jt Infect. 2023;8:29–37.